Tiantan Biological released its 2026 interim report, showing first-half net profit attributable to the parent of 299 million yuan, down 52.7% year on year. Operating revenue was 2.595 billion yuan, down 16.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 285 million yuan, down 53.9% year on year. Net operating cash flow was 289 million yuan, and earnings per share were 0.15 yuan. In the second quarter, operating revenue was 1.45 billion yuan, down 18.9% year on year, and net profit attributable to the parent was 173 million yuan, down 55.4% year on year. As of the end of the second quarter, total assets were 17.045 billion yuan, up 2.8% from the end of the previous year, and net assets attributable to the parent were 11.94 billion yuan, up 1.7% from the end of the previous year. The company said in the interim report that the blood products industry faces multiple constraints on clinical demand and will undergo a period of phased adjustment in the short term, but the industry's strategic importance, raw material scarcity, and resource attributes remain, and blood products maintain rigid demand in specific therapeutic areas. The company is actively promoting comprehensive plasma utilization and developing new products, and expanding markets through international cooperation to respond to market changes.
Beijing Tiantan Biological Products Corp LtdFirst-half net profit attributable to parent fell 52.7% to 299 million yuan, with revenue down 16.6%.
